HCG Share Price Falls 6% While Apollo, Fortis, Max Healthcare Rally; Why Is HCG Falling Today?

Healthcare Global Enterprises (HCG) shares fell nearly 6% on Friday, October 9, moving sharply against a rally in hospital stocks after the government capped trade margins on non-scheduled anti-cancer medicines at 30% of the maximum retail price (MRP).

HCG shares were trading 5.97% lower at ₹600.60 in afternoon trade, while Fortis Healthcare, Apollo Hospitals and Max Healthcare gained as investors assessed the impact of the new cancer drug pricing framework. Fortis rose as much as 5% during the session, while Apollo Hospitals, Max Healthcare and several other hospital stocks gained between 2% and 5%.

The contrasting move put HCG in focus as the company is primarily focused on cancer care, leaving it more directly exposed to changes in oncology drug pricing than diversified hospital chains. HCG Chairman and CEO BS Ajaikumar also raised concerns over the government's intervention, particularly its potential impact on the availability of newer cancer treatments in India.

The government on Thursday approved a 30% cap on margins charged in the supply and sale of non-scheduled anti-cancer drugs, a move expected to reduce prices of affected medicines by as much as 70% and save cancer patients around ₹2,500 crore annually. An expert committee under the Directorate General of Health Services will finalise the medicines that will come under the new framework.

Why Is HCG Falling While Other Hospital Stocks Are Rising?

The difference in Friday's share-price moves reflects the varying exposure of hospital operators to oncology and cancer medicines.

HCG is a cancer-focused healthcare provider, making changes to cancer drug pricing more significant for the company than for larger multi-speciality hospital operators. Ajaikumar said the move may not have a significant immediate impact on HCG but raised concerns over the longer-term consequences of restricting margins on cancer medicines.

The broader hospital pack, meanwhile, rallied after the government settled on a 30% trade margin cap, against the backdrop of a possible 16% margin framework that had come up during recent Supreme Court proceedings. The Supreme Court had questioned steep mark-ups on cancer medicines but had not ordered a nationwide 16% cap.

The 30% framework therefore eased some of the concerns surrounding a potentially tighter cap for diversified hospital operators, while HCG remained under pressure because of its heavier concentration in cancer treatment.

What Does The 30% Cancer Drug Margin Cap Mean?

The new framework applies to non-scheduled anti-cancer medicines, which are not already covered by government-set ceiling prices. Trade margins on the medicines identified under the framework will be capped at 30% of the MRP.

The government expects the move to reduce prices of affected cancer medicines by around 20% to 70%, translating into estimated annual savings of about ₹2,500 crore for patients.

The final list of anti-cancer medicines covered by the measure is yet to be determined. An expert committee under the Directorate General of Health Services will identify the medicines, after which the National Pharmaceutical Pricing Authority will implement the revised framework.

The final list will also provide greater clarity on the impact across hospital operators. For now, Friday's market reaction has highlighted the difference in exposure across the sector, with Apollo Hospitals, Fortis Healthcare and Max Healthcare gained, while oncology-focused HCG fell nearly 6%.

Also Read - ITC Share Price Rises 2% After Hitting 52-Week Low; Stock Down Nearly 30% In 2026